Simple exercise trick may shield cancer patients from chemo nerve pain
NCT ID NCT04652609
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a special exercise program, called PRESIONA, can prevent nerve damage (peripheral neuropathy) caused by chemotherapy in breast cancer patients. The program combines aerobic and strength exercises with blood flow restriction cuffs. Researchers will compare 25 patients doing this program to those receiving usual care, measuring nerve symptoms and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- therapeutic exercise combined with blood flow restriction
- What this could lead to
- If it works, this could offer a drug-free way to prevent painful nerve damage caused by chemotherapy, improving quality of life for breast cancer patients.
- What could go wrong
- This is a very small early study (25 people) with no comparison to other prevention methods. The exercise program may be hard to follow, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 25 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2021
- Expected to finish
-
Jan 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 70 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 18 years or older * HER2+ breast cancer diagnosis * On the waiting list to anticancer medical treatment (taxanes-based neoadjuvant chemotherapy) Exclusion Criteria: * Previous diagnosis of cancer * Pregnant * Cardiac pathology * No symptoms or pathology that could be confused with neuropathy or related to diabetes * No recommendation from oncologist for therapeutic exercise practice
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast neoplasm are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of Granada
RECRUITINGGranada, 18016, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a PI3K inhibitor boost presurgery breast cancer treatment?
- Can a platform trial match the right drug combo to each tumor?
- Can a shorter treatment hold off small HER2-Positive breast cancers?
- Can a Double-Pronged antibody outsmart HER2-Positive tumors?
- Can a pill that blocks Cancer's 'Traffic Signals' stop advanced breast cancer?
- Can a vaccine teach the immune system to fight HER2-Positive tumors?